概括
本综述详细介绍了何时治疗首次发作以及如何管理状态. 它强调了第二次发作的风险和急性和耐火性的有效治疗选择.
科学领域:
- 神经学 神经学
- 临床医学 临床医学
- 症管理 症管理
背景情况:
- 在第一次未引起的发作后,第二次发作的风险是显著的,特别是在EEG异常或脑创伤等危险因素的情况下.
- 急性重复性需要立即服用类,而已确定的状态症需要用类和抗药物分阶段治疗.
研究的目的:
- 为儿童和成年人提供基于证据的指导,治疗未引起的第一次发作.
- 概述急性重复性 (集群) 发作的有效治疗方法.
- 审查确立,耐火和超耐火状态的诊断和管理.
主要方法:
- 审查当前关于扣押管理的证据.
- 针对各种发作类型的治疗干预和剂量指导.
- 对 status epilepticus 的诊断和管理策略进行讨论.
主要成果:
- 第二次发作的风险在2年后为36%,在5年后为46%,由特定的风险因素增加.
- 既定状态的第一线治疗包括类药物,其次是特定的抗发作药物.
- 在添加第二种静脉注射药物或启动连续静脉注射输液之间,Equipoise可用于耐火状态的第三阶段治疗.
结论:
- 基于证据的治疗方案对于管理第一次发作和状态至关重要.
- 现代疗法为急性和难治性发作管理提供了有效的选择.
- 人工智能可能有助于扣押后的临床决策.
相关概念视频
Seizures: Classification
299
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
299
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Sodium Channel Blockers
359
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
359
Antiepileptic Drugs: Glutamate Antagonists
271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219
Antiepileptic Drugs: GABAergic Pathway Potentiators
316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316


